NCT04215523 is a clinical trial of Dapagliflozin in Diabetes, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT04215523?

NCT04215523 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT04215523?

Interventions in NCT04215523: Dapagliflozin, DPP-4 inhibitor.

Is NCT04215523 still recruiting?

NCT04215523 is currently completed. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT04215523

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Replication of the DECLARE Diabetes Trial in Healthcare Claims

Completed Last updated 27 July 2023

What this trial tests

trial testing Dapagliflozin in Diabetes in 49,790 participants. Completed in 18 February 2021.

Timeline

8 July 2019

Primary endpoint
18 February 2021

18 February 2021

Quick facts

Lead sponsor	Brigham and Women's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	49,790
Start date	8 July 2019
Primary completion	18 February 2021
Estimated completion	18 February 2021
Sites	1 location across United States

Drugs / interventions tested

Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
DPP-4 inhibitor — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 120, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Franklin JM, Patorno E, Desai RJ, Glynn RJ, et al · · 2021 · cited 235× · PMID 33327727 · DOI 10.1161/circulationaha.120.051718

Verify or expand the search:

Other trials of Dapagliflozin

Trials testing the same drug.

NCT07491042 — Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. · NA · recruiting
NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07239011 — Dapagliflozin in Depression · Phase 1, PHASE2 · recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04215523 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04215523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing